A Phase 2 interventional study of Nivolumab and Ipilimumab in Advanced Gastric Cancer, sponsored by Bristol-Myers Squibb. Completed at 35 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-09.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Stomach Neoplasms by Bristol-Myers Squibb — 1 open to participants now, 4 under way, 1 of them phase 3. Stomach Neoplasms · Bristol-Myers Squibb.
Among the 14 studies in Stomach Neoplasms by Bristol-Myers Squibb, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 6th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.
Browse Stomach Neoplasms studies →1 of the 14 studies in Stomach Neoplasms by Bristol-Myers Squibb is open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
By country, each count listing its studies:
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 3
First in 2001; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 190 is above the median of 66 across 2,500 interventional studies indexed under Stomach Neoplasms.
Median enrollment 143 across the 10 interventional studies, 500 across the 3 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Stomach Neoplasms by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05165264Bristol-Myers SquibbA Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Stomach Neoplasms by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab · Biological: Ipilimumab
Biological: Nivolumab · Biological: Relatlimab
Biological: Nivolumab · Biological: BMS-986205
Biological: Nivolumab · Drug: Rucaparib
Biological: Ipilimumab · Drug: Rucaparib
Biological: Nivolumab · Biological: Ipilimumab · Drug: Rucaparib
Specified dose on specified days
Also known as: Opdivo, BMS-936558
Specified dose on specified days
Also known as: Yervoy, BMS-734016
Specified dose on specified days
Also known as: BMS-986016
Specified dose on specified days
Specified dose on specified days
Also known as: Rubraca
Objective Response Rate (ORR) by Investigator
ORR is the percent of participants whose best overall response (BOR) is complete response (CR) or partial response (PR). BOR is the best response from the start of the study treatment until objectively documented progression per RECIST v1.1 or subsequent anticancer therapy, whichever occurs first. CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have reduction in short axis to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Response Evaluation Criteria in Solid Tumors (RECIST) is a standard way to measure the response of a tumor to treatment. CR+PR, confidence interval based on Clopper and Pearson method.
Time frame: From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (up to approximately 65 months)
Median Duration of Response (DOR)
Duration of Response (DOR) is the time between the date of first response and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause, whichever occurred first. Complete Response (CR) is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Median computed using Kaplan -Meier method.
Time frame: From first dose to date of first documented tumor progression or death due to any cause, whichever occurred first (up to approximately 65 months)
Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 Weeks
The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Point estimates are derived from Kaplan-Meier analyses, the 95% CIs are derived from Greenwood formula.
Time frame: 24 weeks after first dose
Number of Participants With AEs, SAEs, AEs Leading to Discontinuation, and Death
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose to 100 days after last dose of study therapy (assessed up to approximately 30 months)
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
The number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal.
Time frame: From first dose to 100 days after last dose of study therapy (approximately 30 months)
Number of Participants With Laboratory Abnormalities in Specific Liver Tests
The number of participants with laboratory abnormalities in specific liver tests based on US conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal
Time frame: From first dose to 100 days after last dose of study therapy (approximately 30 months)
| Milestone | Nivolumab + Ipilimumab | Nivolumab + BMS-986016 | Nivolumab + BMS-986205 | Nivolumab + Rucaparib | Ipilimumab + Rucaparib | Nivolumab + Ipilimumab + Rucaparib |
|---|---|---|---|---|---|---|
| Started | 42 | 54 | 62 | 12 | 10 | 10 |
| Randomized to track 1 | 23 | 22 | 38 | 7 | 8 | 6 |
| Randomized to track 2 | 19 | 32 | 24 | 5 | 2 | 4 |
| Completed | 40 | 50 | 59 | 12 | 10 | 10 |
| Not completed | 2 | 4 | 3 | 0 | 0 | 0 |
| Withdrew: Participant withdrew consent | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Other reasons | 0 | 2 | 2 | 0 | 0 | 0 |
| Milestone | Nivolumab + Ipilimumab | Nivolumab + BMS-986016 | Nivolumab + BMS-986205 | Nivolumab + Rucaparib | Ipilimumab + Rucaparib | Nivolumab + Ipilimumab + Rucaparib |
|---|---|---|---|---|---|---|
| Started | 23 | 20 | 38 | 7 | 8 | 6 |
| Re-randomized to track 2 | 2 | 3 | 3 | 0 | 0 | 0 |
| Completed | 1 | 1 | 1 | 0 | 0 | 0 |
| Not completed | 22 | 19 | 37 | 7 | 8 | 6 |
| Withdrew: Disease progression | 15 | 17 | 28 | 4 | 6 | 2 |
| Withdrew: Adverse event unrelated to study drug | 1 | 1 | 2 | 3 | 0 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study drug toxicity | 2 | 1 | 3 | 0 | 0 | 1 |
| Withdrew: Participant request to discontinue treatment | 1 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Participant withdrew consent | 2 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Other reasons | 0 | 0 | 2 | 0 | 0 | 0 |
| Milestone | Nivolumab + Ipilimumab | Nivolumab + BMS-986016 | Nivolumab + BMS-986205 | Nivolumab + Rucaparib | Ipilimumab + Rucaparib | Nivolumab + Ipilimumab + Rucaparib |
|---|---|---|---|---|---|---|
| Started | 23 | 36 | 22 | 6 | 2 | 4 |
| No pre-randomization | 17 | 30 | 21 | 5 | 2 | 4 |
| Re-randomized from track 1 nivolumab + relatlimab | 1 | 0 | 1 | 1 | 0 | 0 |
| Re-randomized from track 1 nivolumab + ipilimumab | 2 | 1 | 0 | 0 | 0 | 0 |
| Re-randomized from track 2 nivolumab + relatlimab | 0 | 2 | 0 | 0 | 0 | 0 |
| Re-randomized from track 2 nivolumab + bms986205 | 3 | 0 | 0 | 0 | 0 | 0 |
| Previously un-treated but re-randomized | 0 | 1 | 0 | 0 | 0 | 0 |
| Re-randomized from track 2 nivolumab + ipilimumab | 0 | 2 | 0 | 0 | 0 | 0 |
| Completed | 1 | 2 | 0 | 1 | 0 | 0 |
| Not completed | 22 | 34 | 22 | 5 | 2 | 4 |
| Withdrew: Disease progression | 13 | 26 | 20 | 5 | 1 | 4 |
| Withdrew: Adverse event unrelated to study drug | 2 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Study drug toxicity | 7 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Participant request to discontinue treatment | 0 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Participant withdrew consent | 0 | 1 | 1 | 0 | 1 | 0 |
ORR is the percent of participants whose best overall response (BOR) is complete response (CR) or partial response (PR). BOR is the best response from the start of the study treatment until objectively documented progression per RECIST v1.1 or subsequent anticancer therapy, whichever occurs first. CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have reduction in short axis to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Response Evaluation Criteria in Solid Tumors (RECIST) is a standard way to measure the response of a tumor to treatment. CR+PR, confidence interval based on Clopper and Pearson method.
| Percent of participants | Track 1: Nivolumab + Ipilimumab | Track 1: Nivolumab + BMS-986016 | Track 1: Nivolumab + BMS-986205 | Track 1: Nivolumab + Rucaparib | Track 1: Ipilimumab + Rucaparib | Track 1: Nivolumab + Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab | Track 2: Nivolumab + BMS-986016 | Track 2: Nivolumab + BMS-986205 | Track 2: Nivolumab + Rucaparib | Track 2: Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab + Rucaparib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) by Investigator | 4.3 (0.1 to 21.9) | 5.0 (0.1 to 24.9) | 13.2 (4.4 to 28.1) | 0 (0.0 to 41.0) | 0 (0.0 to 36.9) | 16.7 (0.4 to 64.1) | 8.7 (1.1 to 28.0) | 5.6 (0.7 to 18.7) | 0 (0.0 to 15.4) | 0 (0.0 to 45.9) | 0 (0.0 to 84.2) | 0 (0.0 to 60.2) |
Duration of Response (DOR) is the time between the date of first response and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause, whichever occurred first. Complete Response (CR) is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Median computed using Kaplan -Meier method.
| Weeks | Track 1: Nivolumab + Ipilimumab | Track 1: Nivolumab + BMS-986016 | Track 1: Nivolumab + BMS-986205 | Track 1: Nivolumab + Rucaparib | Track 1: Ipilimumab + Rucaparib | Track 1: Nivolumab + Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab | Track 2: Nivolumab + BMS-986016 | Track 2: Nivolumab + BMS-986205 | Track 2: Nivolumab + Rucaparib | Track 2: Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab + Rucaparib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median Duration of Response (DOR) | 156.0 (156.0 to 156.0) | NA (113.4 to 113.4) | NA (37.3 to 144.0) | — | — | NA (0.1 to 0.1) | 14.71 (0.1 to 14.71) | 16.86 (8.1 to 25.6) | — | — | — | — |
The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Point estimates are derived from Kaplan-Meier analyses, the 95% CIs are derived from Greenwood formula.
| Proportion of participants | Track 1: Nivolumab + Ipilimumab | Track 1: Nivolumab + BMS-986016 | Track 1: Nivolumab + BMS-986205 | Track 1: Nivolumab + Rucaparib | Track 1: Ipilimumab + Rucaparib | Track 1: Nivolumab + Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab | Track 2: Nivolumab + BMS-986016 | Track 2: Nivolumab + BMS-986205 | Track 2: Nivolumab + Rucaparib | Track 2: Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab + Rucaparib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 Weeks | NA (NA to NA) | NA (NA to NA) | 0.240 (0.114 to 0.393) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 0.170 (0.063 to 0.322) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Track 1: Nivolumab + Ipilimumab | Track 1: Nivolumab + BMS-986016 | Track 1: Nivolumab + BMS-986205 | Track 1: Nivolumab + Rucaparib | Track 1: Ipilimumab + Rucaparib | Track 1: Nivolumab + Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab | Track 2: Nivolumab + BMS-986016 | Track 2: Nivolumab + BMS-986205 | Track 2: Nivolumab + Rucaparib | Track 2: Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab + Rucaparib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Events (AEs) | 23 | 20 | 38 | 7 | 8 | 6 | 23 | 36 | 22 | 6 | 2 | 4 |
| Serious Adverse Events (SAEs) | 19 | 15 | 24 | 5 | 6 | 4 | 17 | 24 | 12 | 4 | 2 | 3 |
| AEs Leading to Discontinuation | 9 | 7 | 11 | 3 | 4 | 4 | 10 | 8 | 2 | 0 | 1 | 0 |
| Death | 19 | 15 | 26 | 7 | 5 | 4 | 19 | 26 | 13 | 3 | 2 | 3 |
The number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal.
| Participants | Track 1: Nivolumab + Ipilimumab | Track 1: Nivolumab + BMS-986016 | Track 1: Nivolumab + BMS-986205 | Track 1: Nivolumab + Rucaparib | Track 1: Ipilimumab + Rucaparib | Track 1: Nivolumab + Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab | Track 2: Nivolumab + BMS-986016 | Track 2: Nivolumab + BMS-986205 | Track 2: Nivolumab + Rucaparib | Track 2: Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab + Rucaparib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TSH > ULN | 4 | 4 | 6 | 1 | 1 | 1 | 11 | 5 | 5 | 0 | 1 | 1 |
| TSH > ULN WITH TSH <= ULN AT BASELINE | 3 | 3 | 4 | 0 | 1 | 1 | 6 | 1 | 4 | 0 | 1 | 0 |
| TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN | 1 | 2 | 2 | 0 | 1 | 1 | 5 | 2 | 2 | 0 | 0 | 1 |
| TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN | 1 | 1 | 1 | 1 | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 0 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 2 | 1 | 3 | 0 | 0 | 0 | 3 | 1 | 3 | 0 | 1 | 0 |
| TSH < LLN | 1 | 2 | 5 | 0 | 0 | 0 | 4 | 6 | 0 | 0 | 0 | 0 |
| TSH <LLN WITH TSH >= LLN AT BASELINE | 0 | 1 | 3 | 0 | 0 | 0 | 3 | 5 | 0 | 0 | 0 | 0 |
| TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN | 1 | 0 | 2 | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 0 |
| TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
The number of participants with laboratory abnormalities in specific liver tests based on US conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal
| Participants | Track 1: Nivolumab + Ipilimumab | Track 1: Nivolumab + BMS-986016 | Track 1: Nivolumab + BMS-986205 | Track 1: Nivolumab + Rucaparib | Track 1: Ipilimumab + Rucaparib | Track 1: Nivolumab + Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab | Track 2: Nivolumab + BMS-986016 | Track 2: Nivolumab + BMS-986205 | Track 2: Nivolumab + Rucaparib | Track 2: Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab + Rucaparib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT OR AST > 3XULN | 6 | 6 | 5 | 1 | 2 | 1 | 6 | 2 | 2 | 3 | 1 | 0 |
| ALT OR AST> 5XULN | 3 | 2 | 3 | 0 | 1 | 1 | 4 | 1 | 0 | 0 | 1 | 0 |
| ALT OR AST> 10XULN | 2 | 1 | 2 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 |
| ALT OR AST > 20XULN | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| TOTAL BILIRUBIN > 2XULN | 2 | 3 | 0 | 1 | 1 | 1 | 3 | 1 | 3 | 1 | 0 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY | 2 | 2 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 1 | 0 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS | 2 | 2 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 1 | 0 | 0 |
Collected over Participants were assessed for all-cause mortality from their randomization until their study completion (up to approximately 65 months). SAEs and other AEs were assessed from first dose to 100 days after last dose of study therapy (up to approximately 30 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Track 1: Nivolumab + Ipilimumab | 19/23 (82.6%) | 19/23 (82.6%) | 21/23 (91.3%) |
| Track 1: Nivolumab + BMS-986016 | 15/23 (65.2%) | 15/20 (75%) | 20/20 (100%) |
| Track 1: Nivolumab + BMS-986205 | 26/39 (66.7%) | 24/38 (63.2%) | 38/38 (100%) |
| Track 1: Nivolumab + Rucaparib | 7/7 (100%) | 5/7 (71.4%) | 7/7 (100%) |
| Track 1: Ipilimumab + Rucaparib | 5/8 (62.5%) | 6/8 (75%) | 8/8 (100%) |
| Track 1: Nivolumab + Ipilimumab + Rucaparib | 4/6 (66.7%) | 4/6 (66.7%) | 6/6 (100%) |
| Track 2: Nivolumab + Ipilimumab | 19/28 (67.9%) | 17/23 (73.9%) | 23/23 (100%) |
| Track 2: Nivolumab + BMS-986016 | 26/41 (63.4%) | 24/36 (66.7%) | 34/36 (94.4%) |
| Track 2: Nivolumab + BMS-986205 | 13/25 (52%) | 12/22 (54.5%) | 21/22 (95.5%) |
| Track 2: Nivolumab + Rucaparib | 3/6 (50%) | 4/6 (66.7%) | 6/6 (100%) |
| Track 2: Ipilimumab + Rucaparib | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) |
| Track 2: Nivolumab + Ipilimumab + Rucaparib | 3/4 (75%) | 3/4 (75%) | 4/4 (100%) |
| Event | Track 1: Nivolumab + Ipilimumab | Track 1: Nivolumab + BMS-986016 | Track 1: Nivolumab + BMS-986205 | Track 1: Nivolumab + Rucaparib | Track 1: Ipilimumab + Rucaparib | Track 1: Nivolumab + Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab | Track 2: Nivolumab + BMS-986016 | Track 2: Nivolumab + BMS-986205 | Track 2: Nivolumab + Rucaparib | Track 2: Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab + Rucaparib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 1/23 | 0/20 | 1/38 | 0/7 | 0/8 | 0/6 | 0/23 | 0/36 | 0/22 | 1/6 | 1/2 | 0/4 |
| HepatitisHepatobiliary disorders | 0/23 | 0/20 | 0/38 | 0/7 | 0/8 | 0/6 | 0/23 | 0/36 | 0/22 | 0/6 | 1/2 | 0/4 |
| PneumoniaInfections and infestations | 1/23 | 0/20 | 2/38 | 0/7 | 0/8 | 0/6 | 0/23 | 0/36 | 0/22 | 1/6 | 1/2 | 0/4 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 11/23 | 6/20 | 11/38 | 0/7 | 3/8 | 0/6 | 5/23 | 9/36 | 8/22 | 2/6 | 1/2 | 2/4 |
| General physical health deteriorationGeneral disorders | 0/23 | 0/20 | 0/38 | 2/7 | 1/8 | 0/6 | 0/23 | 0/36 | 0/22 | 0/6 | 0/2 | 0/4 |
| AnaemiaBlood and lymphatic system disorders | 1/23 | 3/20 | 2/38 | 0/7 | 0/8 | 0/6 | 2/23 | 1/36 | 0/22 | 0/6 | 0/2 | 1/4 |
| Skin bacterial infectionInfections and infestations | 0/23 | 0/20 | 0/38 | 0/7 | 0/8 | 0/6 | 0/23 | 0/36 | 0/22 | 0/6 | 0/2 | 1/4 |
| Acute kidney injuryRenal and urinary disorders | 0/23 | 0/20 | 1/38 | 0/7 | 0/8 | 0/6 | 0/23 | 0/36 | 0/22 | 0/6 | 0/2 | 1/4 |
| AspirationRespiratory, thoracic and mediastinal disorders | 3/23 | 0/20 | 0/38 | 0/7 | 0/8 | 0/6 | 0/23 | 0/36 | 0/22 | 0/6 | 0/2 | 1/4 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/23 | 1/20 | 2/38 | 0/7 | 0/8 | 0/6 | 1/23 | 0/36 | 2/22 | 0/6 | 0/2 | 1/4 |
| Event | Track 1: Nivolumab + Ipilimumab | Track 1: Nivolumab + BMS-986016 | Track 1: Nivolumab + BMS-986205 | Track 1: Nivolumab + Rucaparib | Track 1: Ipilimumab + Rucaparib | Track 1: Nivolumab + Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab | Track 2: Nivolumab + BMS-986016 | Track 2: Nivolumab + BMS-986205 | Track 2: Nivolumab + Rucaparib | Track 2: Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab + Rucaparib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 13/23 | 11/20 | 23/38 | 2/7 | 5/8 | 2/6 | 10/23 | 22/36 | 11/22 | 5/6 | 2/2 | 2/4 |
| NauseaGastrointestinal disorders | 8/23 | 10/20 | 17/38 | 4/7 | 4/8 | 2/6 | 10/23 | 9/36 | 6/22 | 4/6 | 0/2 | 2/4 |
| Alanine aminotransferase increasedInvestigations | 0/23 | 5/20 | 7/38 | 1/7 | 3/8 | 4/6 | 5/23 | 3/36 | 2/22 | 1/6 | 1/2 | 0/4 |
| Aspartate aminotransferase increasedInvestigations | 0/23 | 5/20 | 8/38 | 2/7 | 3/8 | 4/6 | 5/23 | 3/36 | 4/22 | 1/6 | 1/2 | 1/4 |
| DiarrhoeaGastrointestinal disorders | 2/23 | 5/20 | 7/38 | 4/7 | 1/8 | 2/6 | 7/23 | 7/36 | 3/22 | 2/6 | 1/2 | 1/4 |
| TachycardiaCardiac disorders | 0/23 | 0/20 | 1/38 | 0/7 | 0/8 | 0/6 | 0/23 | 0/36 | 0/22 | 0/6 | 1/2 | 0/4 |
| Abdominal painGastrointestinal disorders | 7/23 | 7/20 | 11/38 | 2/7 | 1/8 | 2/6 | 7/23 | 6/36 | 1/22 | 3/6 | 0/2 | 2/4 |
| ConstipationGastrointestinal disorders | 3/23 | 5/20 | 9/38 | 2/7 | 2/8 | 2/6 | 7/23 | 6/36 | 4/22 | 2/6 | 1/2 | 1/4 |
| IleusGastrointestinal disorders | 0/23 | 0/20 | 0/38 | 0/7 | 0/8 | 0/6 | 0/23 | 0/36 | 0/22 | 0/6 | 1/2 | 0/4 |
| Large intestinal obstructionGastrointestinal disorders | 0/23 | 0/20 | 0/38 | 0/7 | 0/8 | 0/6 | 0/23 | 0/36 | 0/22 | 0/6 | 1/2 | 0/4 |
| Age, Continuous(Years) | Track 1: Nivolumab + Ipilimumab | Track 1: Nivolumab + BMS-986016 | Track 1: Nivolumab + BMS-986205 | Track 1: Nivolumab + Rucaparib | Track 1: Ipilimumab + Rucaparib | Track 1: Nivolumab + Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab | Track 2: Nivolumab + BMS-986016 | Track 2: Nivolumab + BMS-986205 | Track 2: Nivolumab + Rucaparib | Track 2: Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab + Rucaparib | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 62.0 ± 11.0 | 58.1 ± 12.6 | 60.6 ± 12.9 | 58.1 ± 10.4 | 57.4 ± 13.9 | 59.5 ± 6.7 | 55.9 ± 12.0 | 61.8 ± 11.8 | 64.2 ± 9.2 | 58.0 ± 16.2 | 57.0 ± 2.8 | 53.0 ± 16.4 | 60.1 ± 11.8 |
| Sex: Female, Male(Participants) | Track 1: Nivolumab + Ipilimumab | Track 1: Nivolumab + BMS-986016 | Track 1: Nivolumab + BMS-986205 | Track 1: Nivolumab + Rucaparib | Track 1: Ipilimumab + Rucaparib | Track 1: Nivolumab + Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab | Track 2: Nivolumab + BMS-986016 | Track 2: Nivolumab + BMS-986205 | Track 2: Nivolumab + Rucaparib | Track 2: Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab + Rucaparib | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 4 | 14 | 0 | 4 | 2 | 2 | 7 | 9 | 1 | 0 | 0 | 48 |
| Male | 18 | 18 | 24 | 7 | 4 | 4 | 17 | 25 | 15 | 4 | 2 | 4 | 142 |
| Ethnicity (NIH/OMB)(Participants) | Track 1: Nivolumab + Ipilimumab | Track 1: Nivolumab + BMS-986016 | Track 1: Nivolumab + BMS-986205 | Track 1: Nivolumab + Rucaparib | Track 1: Ipilimumab + Rucaparib | Track 1: Nivolumab + Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab | Track 2: Nivolumab + BMS-986016 | Track 2: Nivolumab + BMS-986205 | Track 2: Nivolumab + Rucaparib | Track 2: Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab + Rucaparib | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 4 |
| Not Hispanic or Latino | 13 | 17 | 17 | 2 | 2 | 4 | 14 | 25 | 17 | 3 | 2 | 2 | 118 |
| Unknown or Not Reported | 9 | 5 | 20 | 5 | 6 | 2 | 4 | 7 | 6 | 2 | 0 | 2 | 68 |
| Race/Ethnicity, Customized(Participants) | Track 1: Nivolumab + Ipilimumab | Track 1: Nivolumab + BMS-986016 | Track 1: Nivolumab + BMS-986205 | Track 1: Nivolumab + Rucaparib | Track 1: Ipilimumab + Rucaparib | Track 1: Nivolumab + Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab | Track 2: Nivolumab + BMS-986016 | Track 2: Nivolumab + BMS-986205 | Track 2: Nivolumab + Rucaparib | Track 2: Ipilimumab + Rucaparib | Track 2: Nivolumab + Ipilimumab + Rucaparib | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 22 | 19 | 32 | 7 | 7 | 6 | 13 | 29 | 19 | 4 | 1 | 3 | 162 |
| Black or African American | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 3 | 0 | 1 | 1 | 9 |
| Asian | 1 | 2 | 1 | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 0 | 9 |
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other | 0 | 1 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 6 |
| Not reported | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in May 2022, 65 months.
Results were first posted in Jun 2023, 1 year after primary completion.
Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 65 months is above that.
Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Relatlimab · Linrodostat · Rucaparib